Literature DB >> 21283095

Trial watch: phase III and submission failures: 2007-2010.

John Arrowsmith.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21283095     DOI： 10.1038/nrd3375

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  129 in total

1.  Reinventing clinical trials.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  Oncology trials--the elephant in the room.

Authors:  Rebecca Kirk; Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2012-03-28       Impact factor: 66.675

3.  Networking for new drugs.

Authors:  Claire Ainsworth
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

Review 4.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

5.  Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.

Authors:  Timothy C Guetterman; Michael D Fetters; Laurie J Legocki; Samkeliso Mawocha; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Res Regul Aff       Date:  2015-09-18

Review 6.  At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.

Authors:  Mark Penney; Balaji Agoram
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 7.  Reproducibility of research and preclinical validation: problems and solutions.

Authors:  Lajos Pusztai; Christos Hatzis; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2013-10-01       Impact factor: 66.675

8.  Bringing together the academic drug discovery community.

Authors:  Barbara S Slusher; P Jeffrey Conn; Stephen Frye; Marcie Glicksman; Michelle Arkin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

Review 9.  Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Authors:  Joaquin Mateo; Michael Ong; David S P Tan; Michael A Gonzalez; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2013-10-15       Impact factor: 66.675

10.  A stronger role for science.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.